Ability of two commercially available assays (Abbott RealTime HIV-1 and Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2.0) to quantify low HIV-1 RNA levels (<1,000 copies/milliliter): Comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays

Journal of Clinical Microbiology

Volumn 52, Issue 6, 2014, Pages 2019-2026

  Amendola, Alessandra ^a   Marsella, Patrizia ^a   Bloisi, Maria ^a   Forbici, Federica ^a   Angeletti, Claudio ^a   Capobianchi, Maria R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ABBOTT ASSAY; ARTICLE; COMMERCIAL PHENOMENA; CONTROLLED STUDY; DIAGNOSTIC KIT; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REACTION OPTIMIZATION; ROCHE ASSAY; SENSITIVITY ANALYSIS; VIRUS LOAD; BLOOD; COMPARATIVE STUDY; EVALUATION STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; MOLECULAR DIAGNOSIS; PROCEDURES; SENSITIVITY AND SPECIFICITY; VIROLOGY;

HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 84901660829     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00288-14     Document Type: Article

References (44)

1. WHO. 2014. March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement- march2014
2. British HIV Association. 2014. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy. HIV Med. 15(Suppl 1):1-85. http://dx.doi.org/10.1111/hiv.12119
3. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, Eron JJ, Gunthard HF, Hammer SH, Reiss P, Richman DD, Rizzardini G, Thomas DL, Jacobsen DM, Volberding PA. 2012. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA 308:387-402. https://www.iasusa.org/content/antiretroviral-treatment-adult-hiv- infection-0
4. European AIDS Clinical Society. 2013. Guidelines, version 7.0, October 2013. European AIDS Clinical Society, Brussels, Belgium. http://www .eacsociety.org/Portals/0/Guidelines-Online-131014.pdf.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. 2014. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Office of AIDS Research Advisory Council (OARAC), Rockville, MD. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
6. Grennan JT, Loutfy MR, Su D, Harrigan PR, Cooper C, Klein M, Machouf N, Montaner JS, Rourke S, Tsoukas C, Hogg B, Raboud J, CANOC Collaboration. 2012. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J. Infect. Dis. 205:1230-1238. http://dx.doi.org/10.1093/infdis/jis104
7. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H. 2013. Virologic failure following persistent low-level viremia in a cohort of HIVpositive patients: results from 12 years of observation. Clin. Infect. Dis. 57:1489-1496. http://dx.doi.org/10.1093/cid/cit529
8. Doyle T, Smith C, Vitiello P, Cambiano V, Johnson M, Owen A, Phillips AN, Geretti AM. 2012. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 54:724-732. http://dx.doi.org/10.1093/cid/cir936
9. Gandhi RT, Bosch RJ, Aga E, Bedison MA, Bastow B, Schmitz JL, Siliciano JD, Siliciano RF, Eron JJ, Mellors JW, ACTGA5173 Team. 2013. Residual plasma viraemia and infectious HIV-1 recovery from resting memory CD4 cells in patients on antiretroviral therapy: results from ACTG A5173. Antivir. Ther. 18:607-613. http://dx.doi.org/10.3851/IMP2543
10. Maggiolo F, Callegaro A, Cologni G, Bernardini C, Velenti D, Gregis G, Quinzan G, Soavi L, Iannotti N, Malfatto E, Leone S. 2012. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J. Acquir. Immune Defic. Syndr. 60:473-482. http://dx.doi.org/10.1097/QAI.0b013e3182567a57
11. Pugliese P, Delpierre C, Cuzin L, Poizot-Martin I, Rey D, Saune K, Cottalorda J, Bettinger D, Delaugerre C, Hoen B, Dat AIDS Study Group. 2013. An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy. HIV Med. 14:509-515. http://dx.doi.org/10. 1111/hiv.12041
12. Álvarez Estévez M, Chueca Porcuna N, Guillot Suay V, Peña Monge A, García García F, Muñoz Medina L, Vinuesa García D, Parra Ruiz J, Hernández-Quero J, García García F. 2013. Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to 50 copies per milliliter. J. Clin. Microbiol. 51: 1555-1557. http://dx.doi.org/10.1128/JCM. 00100-13
13. Sire JM, Vray M, Merzouk M, Plantier JC, Pavie J, Maylin S, Timsit J, Lascoux-Combe C, Molina JM, Simon F, Delaugerre C. 2011. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott RealTime HIV-1 PCR assays. J. Acquir. Immune Defic. Syndr. 56:239-243. http://dx.doi.org/10.1097/QAI.0b013e3182099891
14. Wall GR, Perinpanathan D, Clark DA. 2012. Comparison of the Qiagen artus HIV-1 QS-RGQ test with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test v2.0. J. Clin. Virol. 55:62-66. http://dx.doi.org/10.1016/j.jcv.2012.05.014
15. Garcia-Diaz A, Labbett W, Clewley GS, Guerrero-Ramos A, Geretti AM. 2013. Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma. J. Clin. Virol. 57:66-69. http://dx.doi.org/10.1016/j.jcv.2013.01.006
16. Amendola A, Milia MG, Ghisetti V, Brega C, Zaccaro P, Capobianchi MR. 2009. Accuracy of a commercial real-time polymerase chain reaction-based system for measurement of HIVRNAlevels around the limit of quantification of the assay. Clin. Infect. Dis. 48:1630-1631. http://dx.doi.org/10.1086/598990
17. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, Cunningham PH. 2010. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J. Clin. Virol. 49:249-253. http://dx.doi.org/10.1016/j.jcv.2010.08.016
18. Karasi JC, Dziezuk F, Quennery L, Förster S, Reischl U, Colucci G, Schoener D, Seguin-Devaux C, Schmit JC. 2011. High correlation between the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. J. Clin. Virol. 52:181-186. http://dx.doi.org/10.1016/j.jcv.2011.07.002
19. Glaubitz J, Sizmann D, Simon CO, Hoffmann KS, Drogan D, Hesse M, Lang G, Kroeh M, Simmler P, Dewald M, Haberhausen G, Lindauer A, Beyser K, Reber A, Baumeister A, Wolf E, Jaeger H, Babiel R. 2011. Accuracy to 2nd International HIV-1 RNAWHOStandard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J. Clin. Virol. 50:119-124. http://dx.doi.org/10.1016/j.jcv.2010.10.017
20. van Rensburg EJ, Tait K, Watt A, Schall R. 2011. Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test using the TaqMan 48 analyzer and the Abbott RealTime HIV-1 assay. J. Clin. Microbiol. 49:377-379. http://dx.doi.org/10.1128/JCM.01285-10
21. Taylor N, Grabmeier-Pfistershammer K, Egle A, Greil R, Rieger A, Ledergerber B, Oberkofler H. 2013. Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level. PLoS One 8:e74024. http://dx.doi.org/ 10.1371/journal.pone.0074024
22. Amendola A, Bloisi M, Marsella P, Sabatini R, Bibbò A, Angeletti C, Capobianchi MR. 2011. Standardization and performance evaluation of "modified" and "ultrasensitive" versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. J. Clin. Virol. 52:17-22. (Erratum 53:181, 2012.) http://dx.doi.org/10.1016/j.jcv.2011. 04.012
23. Davis C, Heath A, Best S, Hewlett I, Lelie N, Schuurman R, Holmes H. 2003. Calibration of HIV-1 working reagents for nucleic acid amplification techniques against the 1st International Standard for HIV-1 RNA. J. Virol. Methods 107:37-44. http://dx.doi.org/10.1016/S0166-0934(02)00187-8 (Pubitemid 35373905)
24. Lin LI. 1989. A concordance correlation coefficient to evaluate reproducibility. Biometrics 45:255-268
25. Bland JM, Altman DG. 1986. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet i:307-310 (Pubitemid 16134762)
26. Finney DJ. 1971 Probit analysis, 3rd ed. Cambridge University Press, Cambridge, United Kingdom.
27. Collett D. 2003. Modelling binary data, 2nd ed. Chapman and Hall, New York, NY.
28. Paba P, Fabeni L, Ciccozzi M, Perno CF, Ciotti M. 2011. Performance evaluation of the Cobas/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: a comparative study. J. Virol. Methods 173:399-402. http://dx.doi.org/10.1016/j.jviromet.2011.03.014
29. Wirden M, Tubiana R, Marguet F, Leroy I, Simon A, Bonmarchand M, Ait-Arkoub Z, Murphy R, Marcelin AG, Katlama C, Calvez V. 2009. Impact of discrepancies between the Abbott RealTime and Cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group Mnon-B subtypes. J. Clin. Microbiol. 47:1543-1545. http://dx.doi.org/10.1128/JCM.02134-08
30. Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, Berger A. 2013. Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia. Med. Microbiol. Immunol. 202:67-75. http://dx.doi.org/10.1007/s00430-012-0249-y.
31. Swenson LC, Cobb B, Geretti AM, Harrigan PR, Poljak M, Seguin-Devaux C, Verhofstede C, Wirden M, Amendola A, Boni J, Bourlet T, Huder JB, Karasi JC, Lepej SZ, Lunar MM, Mukabayire O, Schuurman R, Tomažič J, Van Laethem K, Vandekerckhove L, Wensing AMJ. 2013. Comparative performance of HIV-1 RNA load assays at low viral load levels: results of an international collaboration. J. Clin. Microbiol., in press. http://dx.doi.org/10.1128/JCM. 02461-13
32. Taylor N, Schmid I, Egle A, Greil R, Patsch W, Oberkofler H. 2009. Initial evaluation of the Roche Cobas TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals. Antivir. Ther. 14:1189-1193. http://dx.doi.org/10.3851/IMP1427
33. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, Yao JDC. 2009. Comparison of the Abbott RealTime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J. Clin. Microbiol. 47: 889-895. http://dx.doi.org/10.1128/JCM. 02231-08
34. Sire JM, Vray M, Merzouk M, Plantier JC, Pavie J, Maylin S, Timsit J, Lascoux-Combe C, Molina JM, Simon F, Delaugerre C. 2011. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott RealTime HIV-1 PCR assays. J. Acquir. Immune Defic. Syndr. 56:239-243. http://dx.doi.org/10.1097/QAI.0b013e3182099891
35. Ruelle J, Debaisieux L, Vancutsem E, De Bel A, Delforge ML, Piérard D, Goubau P. 2012. HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability. BMC Infect. Dis. 12:100. http://dx.doi.org/10.1186/1471-2334-12-100
36. Karlsson AC, Younger SR, Martin JN, Grossman Z, Sinclair E, Hunt PW, Hagos E, Nixon DF, Deeks SG. 2004. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 18:981-989. http://dx.doi.org/10.1097/00002030-200404300-00005 (Pubitemid 38591188)
37. Aleman S, Söderbärg K, Visco-Comandini U, Sitbon G, Sönnerborg A. 2002. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS 16:1039-1044. http://dx.doi.org/10.1097/00002030-200205030-00010 (Pubitemid 34499427)
38. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ, Jr. 2011. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy. J. Infect. Dis. 204:515-520. http://dx.doi.org/10.1093/infdis/jir353
39. Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina JM, de Truchis P. 2012. Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treatedpatients. PLoS One 7:e36673. http://dx.doi.org/10.1371/journal.pone.0036673
40. Scott L, Carmona S, Stevens W. 2009. The performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay. J. Clin. Microbiol. 47:3400-3402. http://dx.doi.org/10.1128/JCM.00727-09
41. Troppan KT, Stelzl E, Violan D, Winkler M, Kessler HH. 2009. Evaluation of the new Versant HIV-1 RNA 1.0 assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA. J. Clin. Virol. 46:69-74. http://dx.doi.org/10.1016/j.jcv.2009.06.012
42. Bourlet T, Signori-Schmuck A, Roche L, Icard V, Saoudin H, Trabaud MA, Tardy JC, Morand P, Pozzetto B, Ecochard R, André P. 2011. HIV-1 load comparison using four commercial real-time assays. J. Clin. Microbiol. 49:292-297. http://dx.doi.org/10.1128/JCM.01688-10
43. Henrich TJ, Wood BR, Kuritzkes DR. 2012. Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load 48 copies/ml. PLoS One 7:e50065. http://dx.doi.org/10.1371/journal.pone.0050065
44. Gianotti N, Galli L, Salpietro S, Cernuschi M, Bossolasco S, Maillard M, Spagnuolo V, Canducci F, Clementi M, Lazzarin A, Castagna A. 2013. Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clin. Microbiol. Infect. 19:E542-E544. http://dx.doi.org/10.1111/1469-0691.12266.